Literature DB >> 25190230

Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy.

Martin H Ruwald1, Suneet Mittal2, Anne-Christine Ruwald3, Mehmet K Aktas4, James P Daubert5, Scott McNitt4, Amin Al-Ahmad6, Christian Jons7, Valentina Kutyifa4, Jonathan S Steinberg2, Paul Wang8, Arthur J Moss4, Wojciech Zareba4.   

Abstract

BACKGROUND: A high percentage of biventricular pacing is required for optimal outcome in patients treated with cardiac resynchronization therapy (CRT), but the influence of ectopic beats on the success of biventricular pacing has not been well established.
OBJECTIVES: This study sought to determine if increased ectopic beats reduce the chance of high biventricular pacing percentage and are associated with subsequent adverse outcomes.
METHODS: From the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy), 801 patients with an implanted CRT-defibrillator device with data available on biventricular pacing percentage and pre-implantation 24-h Holter recordings were included. Using logistic regression, we estimated the influence of ectopic beats on the percentage of biventricular pacing. Reverse remodeling was measured as reductions in atrial and left ventricular end-systolic volumes (LVESV) at 1 year. Cox models were used to assess the influence of ectopic beats on the outcomes of heart failure (HF) or death, ventricular tachyarrhythmias (VTAs), and death.
RESULTS: In the pre-implantation Holter recording, ectopic beats accounted for a mean 3.2 ± 5.5% of all beats. The probability of subsequent low biventricular pacing percentage (<97%) was increased 3-fold (odds ratio: 3.37; 95% confidence interval: 1.74 to 6.50; p < 0.001) in patients with 0.1% to 1.5% ectopic beats and 13-fold (odds ratio: 13.42; 95% confidence interval: 7.02 to 25.66; p < 0.001) in patients with >1.5% ectopic beats compared with those with <0.1% ectopic beats. Patients with ≥0.1% ectopic beats had significantly less reverse remodeling (percent reduction in LVESV 31 ± 15%) than patients with <0.1% ectopic beats (percent reduction in LVESV 39 ± 14%; p < 0.001). The risk of HF/death and VTA was increased significantly in those with 0.1% to 1.5% ectopic beats (hazard ratio: 3.13 and 1.84, respectively) and for >1.5% ectopic beats (hazard ratio: 2.38 and 2.74, respectively).
CONCLUSIONS: Relatively low frequencies of ectopic beats (≥0.1%) dramatically increase the probability of low biventricular pacing (<97%), with reduced CRT efficacy by less reverse remodeling and higher risk of HF/death and VTA. This supports pre-implantation Holter monitoring of patients selected for CRT for optimal outcome. (MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Holter monitoring; biventricular pacing; cardiac resynchronization therapy; ectopic beats; prognosis; reverse remodeling

Mesh:

Year:  2014        PMID: 25190230     DOI: 10.1016/j.jacc.2014.06.1177

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

Review 1.  Non-response to Cardiac Resynchronization Therapy.

Authors:  Syed Yaseen Naqvi; Anas Jawaid; Ilan Goldenberg; Valentina Kutyifa
Journal:  Curr Heart Fail Rep       Date:  2018-10

2.  Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy.

Authors:  Anne-Christine Ruwald; Mehmet K Aktas; Martin H Ruwald; Valentina Kutyifa; Scott McNitt; Christian Jons; Suneet Mittal; Jonathan S Steinberg; James P Daubert; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-20       Impact factor: 1.468

3.  The Burden and Morphology of Premature Ventricular Contractions and their Impact on Clinical Outcomes in Patients Receiving Biventricular Pacing in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT).

Authors:  Mehmet K Aktas; Suneet Mittal; Valentina Kutyifa; Scott McNitt; Bronislava Polonsky; Jonathan Steinberg; Arthur J Moss; Wojciech Zareba
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-02-16       Impact factor: 1.468

Review 4.  [Management of premature ventricular ectopy in cardiac resynchronization therapy : Treatment strategies for an optimized cardiac resynchronization].

Authors:  Benjamin Rath; Julia Köbe; Florian Reinke; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-01-29

Review 5.  Mechanisms, time course and predictability of premature ventricular contractions cardiomyopathy-an update on its development and resolution.

Authors:  C Cojocaru; D Penela; Antonio Berruezo; R Vatasescu
Journal:  Heart Fail Rev       Date:  2021-09-12       Impact factor: 4.654

6.  Effect of single ventricular premature contractions on response to cardiac resynchronization therapy.

Authors:  Annamária Kosztin; Béla Merkely; Eperke Dóra Merkel; András Mihaly Boros; Walter Richárd Schwertner; Anett Behon; Attila Kovács; Bálint Károly Lakatos; László Gellér
Journal:  BMC Cardiovasc Disord       Date:  2022-06-25       Impact factor: 2.174

Review 7.  Update on ventricular tachyarrhythmias and related sudden cardiac death.

Authors:  Johnson Francis; Narayanan Namboodiri
Journal:  Indian Pacing Electrophysiol J       Date:  2014-12-15

8.  Dual intraventricular response after cardiac resynchronization.

Authors:  Philippe Debruyne; Peter Haemers
Journal:  HeartRhythm Case Rep       Date:  2017-05-04

Review 9.  Advances in Cardiac Resynchronization Therapy.

Authors:  Asif Jafferani; Miguel A Leal
Journal:  J Innov Card Rhythm Manag       Date:  2019-06-15

Review 10.  Pathophysiology, diagnosis and treatment of tachycardiomyopathy.

Authors:  Claire A Martin; Pier D Lambiase
Journal:  Heart       Date:  2017-08-30       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.